Today Ely Lilly (LLY) announced the positive results on a phase 2 diabetes drug of theirs ( LY3298176 ) via a publication in The Lancet, a presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) and the press release below: Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes The press release created a few headlines: Bloomberg: Diabetes Drug's Results Push Lilly to Look at Obesity Too Reuters: Lilly's diabetes drug data impresses, hurts rival Novo's shares The share price of Eli Lilly went up by 4% in an otherwise sour market and that of Danish rival Novo Nordisk (NOVO-B.CO) plummeted some 7-8%
Wagner S, Brierley DI, Leeson-Payne A, Jiang W, Chianese R, Lam BY, et al
Additionally, the increased physical activity accompanying most weight loss programs generates its own inflammatory load
If a brand has cultivated loyal users over time, that pattern typically reflects reliable delivery week after week rather than a single short-term promotion
~ AlphaMD When it comes to weight loss, most people focus on diet and exercise, but hormones also play a crucial role
Basaglar provides predictable basal insulin coverage for consistent fasting glucose control
